drugset
drugset / Trial / NCT05633745

A Study to Assess NEU-723 in Healthy Participants

NCT05633745 ↗

Phase 1 Terminated 40 enrolled Neuron23 Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), of orally administered NEU-723 in healthy subjects.

Timeline

Start
2023-01-30
Primary completion
2023-06-30
Completion
2023-06-30

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject NEU-723 Unknown — Oral

Indications

No indication recorded.